Search Within

Steven M Horwitz

Formats
  1. Meeting Abstract (374)
  2. Journal Article (248)
  3. Review (13)
  4. Guidelines (11)
  5. Research Letter (9)
  6. Book Section (6)
  7. Correspondence (5)
  8. Editorial (4)
  9. Miscellaneous (1)
Groups
  1. Center for Hematologic Malignancies (671)
  2. Department of Medicine (671)
  3. Hematologic Malignancies, Division of (671)
  4. Lymphoma (671)
  5. Population Sciences Research Program (671)
  6. Survivorship Research (173)

More Groups

People
  1. Alison Moskowitz (235)
  2. Andrew Zelenetz (169)
  3. Paul Hamlin (140)
  4. Ariela Noy (139)
  5. David Straus (122)
  6. Maria Palomba (112)

More People

Years
  1. 2025 (18)
  2. 2024 (51)
  3. 2023 (41)
  4. 2022 (34)
  5. 2021 (53)
  6. 2020 (52)

More Years

Publications
  1. Blood (255)
  2. Journal of Clinical Oncology (64)
  3. Hematological Oncology (38)
  4. Blood Advances (19)
  5. Leukemia and Lymphoma (19)
  6. Annals of Oncology (18)

More Publications

Publishers
  1. American Society of Hematology (277)
  2. American Society of Clinical Oncology (65)
  3. Wiley Blackwell (55)
  4. Elsevier Inc. (34)
  5. Oxford University Press (25)
  6. Taylor & Francis Group (23)

More Publishers

Results (671)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Clinicopathologic characteristics of HIV-associated peripheral T-cell lymphoma
    Meeting Abstract

    Castillo, J.; Beltran, B.; Collins, J.; Diez-Martin, J. L.; Hernandez-Ilizaliturri, F.; Horwitz, S. M.; Vose, J. M.
    Blood (2009)

    Fulltext@MSK | Save
  • Stem cell transplant (SCT) and pralatrexate therapy: Outcome of patients with relapsed or refractory peripheral T-cell lymphoma who received SCT prior to or following pralatrexate therapy
    Meeting Abstract

    Popplewell, L.; Pro, B.; Jacobsen, E.; Horwitz, S. M.; Boyd, A.; Patterson, M.; Fruchtman, S.; O'Connor, O. A.
    Blood (2009)

    Fulltext@MSK | Save
  • Negative interim FDG-PET scan is predictive of superior outcome in T cell lymphoma
    Meeting Abstract

    Casulo, C.; Zelenetz, A. D.; Moskowitz, C. H.; Horwitz, S. M.
    Blood (2009)

    Fulltext@MSK | Save
  • Safety and management of pralatrexate treatment in relapsed or refractory peripheral T-cell lymphoma (PTCL)
    Meeting Abstract

    Pinter-Brown, L.; Horwitz, S. M.; Pro, B.; Zinzani, P. L.; Gisselbrecht, C.; Cortelli, B. M.; Fruchtman, S.; O'Connor, O. A.
    Blood (2009)

    Fulltext@MSK | Save
  • Pralatrexate induces responses in patients with highly refractory peripheral T-cell lymphoma (PTCL)
    Meeting Abstract

    Savage, K. J.; Shustov, A. R.; Goy, A.; Horwitz, S. M.; Pro, B.; Patterson, M.; Fruchtman, S.; O'Connor, O. A.
    Blood (2009)

    Fulltext@MSK | Save
  • Correlation between baseline methylmalonic acid status and mucositis severity in the PROPEL study: Implications for vitamin prophylaxis
    Meeting Abstract

    Pro, B.; Coiffier, B.; Horwitz, S. M.; Boyd, A.; Neylon, E.; Fruchtman, S.; O'Connor, O. A.
    Blood (2009)

    Fulltext@MSK | Save
  • Pralatrexate and gemcitabine in patients with relapsed or refractory lymphoproliferative malignancies: Phase 1 results
    Meeting Abstract

    Horwitz, S. M.; Vose, J. M.; Advani, R.; Sankhala, K.; Padmanabhan, S.; Hamlin, P. A. Jr; Chen, A.; Zain, J. M.; Fruchtman, S.; O'Connor, O. A.
    Blood (2009)

    Fulltext@MSK | Save
  • Pralatrexate is active in cutaneous T-cell lymphoma (CTCL): Results of a multicenter, dose-finding trial
    Meeting Abstract

    Horwitz, S. M.; Duvic, M.; Kim, Y.; Zairi, J. M.; Lechowicz, M. J.; Myskowski, P.; Fruchtman, S.; O'Connor, O. A.
    Blood (2009)

    Fulltext@MSK | Save
  • Bendamustine is highly active in heavily pre-treated relapsed and refractory Hodgkin lymphoma and serves as a bridge to allogeneic stem cell transplant
    Meeting Abstract

    Moskowitz, A. J.; Hamlin, P. A.; Gerecitano, J.; Horwitz, S. M.; Matasar, M.; Meikle, J.; Noy, A.; Palomba, M. L.; Portlock, C. S.; Straus, D. J.; more...
    Blood (2009)

    Fulltext@MSK | Save
  • Phase II-I-II study of two different doses and schedules of pralatrexate, a high-affinity substrate for the reduced folate carrier, in patients with relapsed or refractory lymphoma reveals marked activity in T-cell malignancies
    Journal Article

    O'Connor, O. A.; Horwitz, S.; Hamlin, P.; Portlock, C.; Moskowitz, C. H.; Sarasohn, D.; Neylon, E.; Mastrella, J.; Hamelers, R.; Macgregor-Cortelli, B.; more...
    Journal of Clinical Oncology (2009)

    Fulltext@MSK | Save